Protagenic Therapeutics I... (PTIX)
NASDAQ: PTIX
· Real-Time Price · USD
3.22
-0.10 (-3.01%)
At close: Sep 12, 2025, 3:59 PM
3.33
3.42%
After-hours: Sep 12, 2025, 07:46 PM EDT
Company Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
The company is based in New York, New York.
Protagenic Therapeutics Inc.
| Country | United States |
| IPO Date | Apr 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Garo H. Armen |
Contact Details
Address: 149 Fifth Avenue New York City, New York United States | |
| Website | https://www.protagenic.com |
Stock Details
| Ticker Symbol | PTIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001022899 |
| CUSIP Number | 74365N301 |
| ISIN Number | US74365N2027 |
| Employer ID | 06-1390025 |
| SIC Code | 7389 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander Kenneth Arrow C.F.A., M.D. | Chief Financial Officer & Secretary |
| Dr. Andrew Slee Ph.D. | Chief Operating Officer |
| Dr. Garo H. Armen Ph.D. | Co-Founder & Executive Chairman of the Board |
| Dr. Robert Benjamin Stein M.D., Ph.D. | Chief Medical Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2025 | 10-QT | Filing |
| Aug 28, 2025 | 8-K/A | [Amend] Current Report |
| Aug 25, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 22, 2025 | 8-K | Current Report |
| Aug 14, 2025 | NT 10-Q | Filing |
| Aug 13, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 24, 2025 | 8-K | Current Report |
| Jul 08, 2025 | SCHEDULE 13G | Filing |
| Jun 27, 2025 | 8-K | Current Report |